PALVELLA THERAPEUTICS, INC. (PVLA) research
PALVELLA THERAPEUTICS, INC.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $132.47
- As of
PALVELLA THERAPEUTICS, INC. (PVLA): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-04.
As of . Source: SEC EDGAR filings for PVLA. Method and limitations.
Share the PVLA intelligence card
See the full PVLA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PVLA on one page. Preview it with sample data, then open it live with a free account.
Preview the PVLA dossierActive signals for PVLA
- highCONSENSUS_BUY
3 tracked funds increased PVLA this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +196% to PVLA (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +405% to PVLA (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1053% to PVLA (2026Q2)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +151% to PVLA (2026Q2)
FREE, NO ACCOUNT
Every signal on PVLA, as it fires
You are seeing 5 of 10 signals recorded on PVLA since 2026-05-30.
The five above landed across 2 days. The other 5 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in PVLA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 697947109 · 2026Q2 | $8.1M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 697947109 · 2026Q2 | $8M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 697947109 · 2026Q2 | $1.9M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 697947109 · 2026Q2 | $538K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, PVLA
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
PVLA against its peers
PVLA's return on equity of -149.1% ranks in the 13th percentile of 18 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | PVLA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 108M | n/a | 16 |
| Operating margin | n/a | -100.5% | n/a | 16 |
| Net margin | n/a | -76.6% | n/a | 17 |
| Return on equity | -149.1% | -32.4% | 13 | 18 |
| P / E | n/a | 7.6x | n/a | 5 |
Peers (22): URGN, SRPT, AGIO, RXRX, VCEL, BHVN, LKFT, ZYME, BCRX, XNCR, MESO, AUPH, CMPS, SEPN, PHVS, ZBIO, MLYS, ADMA, NVAX, VIR, VRDN, VERA. Left out: GENB (no annual filing), BRVE (no annual filing), ADRX (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (PVLA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more PVLA signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to PVLAand get the insider, 13F, options, and confluence read in one view.